@col69 Firstly - thank you for all of your contributions over the years. I greatly appreciate the time and effort you put into your insights and sleuthing.
I agree they better get a deal made on CHF (or CLBP) THIS calendar year.
Based on the total addressable market opportunity of 2,500 LVADs (per MSB) and 1,025 babies (see link below) of these two indications - any deal would likely be a smaller upfront and would be scaled so larger payments are made as the larger patients cohorts (class II and III) are approved/marketable.
Do we have any indication on Revascor pricing?https://www.cdc.gov/ncbddd/heartdefects/hlhs.html
@col69 Firstly - thank you for all of your contributions over...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64999 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 64541 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |